This study addressed the dearth of information on the incidence of psychiatric disorders related to corticosteroid-containing treatment in patients with hematologic malignancies.
Researchers sought to determine if nonmyeloablative HSCT conditioning was noninferior to myeloablative approaches in more vulnerable patients with AML.
Patients with acute myeloid leukemia and myelodysplastic syndromes reported similar quality of life irrespective of the conditioning regimen the received.
This study investigated whether T-cell gene-expression profiles and other molecular characteristics of T-cell populations were associated with CAR-T performance.
Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.
The response rate to 19-28z CAR-T therapy was 100% for those with pretreatment MRD who received preconditioning chemotherapy with high-dose cyclophosphamide.
Using EQ-5D and PedsQL, researchers determined the long-term effect of tisagenlecleucel treatment on quality of life for pediatric and young patients with R/R B-cell ALL.
The risk for second primary malignancy appeared to increase over time in survivors of chronic lymphocytic leukemia compared with the general population.
Factors associated with survival in chronic myeloid leukemia diagnosed in advanced phase or blast crisis included blast count, age, and hemoglobin level.
A retrospective evaluation of patients with leukemia or lymphoma treated with CAR-T therapy determined their likelihood of experiencing refractory colitis associated with the treatment.
Researchers are assessing the value and safety of discontinuing TKI therapy in patients with chronic phase CML who have achieved deep molecular response.
A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy.
Nilotinib was associated with high adherence to treatment and fairly high quality of life, and nearly all evaluated patients achieved a major molecular response.
This trial employed chemotherapy-free induction therapy followed by assessment of MRD status to triage patients for subsequent therapy with or without chemotherapy.
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported.
The Food and Drug Administration (FDA) has approved Ruxience (rituximab-pvvr; Pfizer), a biosimilar to Rituxan (Genentech and Biogen), for the treatment of adult patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangitis and microscopic polyangiitis. The approval was based on a comprehensive data package which included results from the REFLECTIONS B3281006 study in…
Many clinical and ethical factors influence whether preemptive transplant would be beneficial for patients genetically predisposed to acute myeloid leukemia.
